secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001193125-26-006998
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan reports $439M cash as of Dec 31, 2025; outlines 2026 clinical milestones for CLN-978, CLN-049, zipalertinib
--------------------------------------------------------------------------------

- Preliminary cash, equivalents, investments, interest receivable $439.0M at Dec 31, 2025; runway into 2029.
- CLN-978: Phase 1 dose escalation in RA, SLE, SjD ongoing; initial data readouts in Q2/Q3/Q4 2026.
- CLN-049: Fast Track for relapsed/refractory AML; dose expansion to determine RP2D in Q4 2026; pivotal trial expected.
- Zipalertinib: NDA submission completion expected Q1 2026; REZILIENT3 enrollment complete H1 2026; $130M US milestones + 50% profit share.
- Velinotamig: Genrix Bio Phase 1 in China initiated; initial data in Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000119312526006998/0001193125-26-006998-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000119312526006998/cgem-20260108.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-006998

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer